Explore 3 Stock Ideas & Industry Insights Download Free Report

BSF Enterprise Plc

Company price
0.0452 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
10000
Market Cap
3.63M

Momentum Score

…

BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.05
High
52 Week Price Range
0.00
Low
0.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BSF Enterprise Plc is a publicly quoted company on the OTC Pink market under ticker BSFAF; there is limited public information on its core operations and financial condition. Long-term growth may benefit from clearer disclosure, execution of any business plan and access to capital; investors should monitor filings and management updates.

Key risks are limited disclosure, very low liquidity, potential share dilution and operational uncertainty typical of OTC Pink issuers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
0.05M
Revenue Per Share
0.01
Gross Profit TTM
-0.05M
Debt / Equity
-
ROE
-37.69%
Net Debt
-
ROCE
-44.46%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -1.22M -1.80M -1.58M -0.93M -0.06M
Net income -1.11M -1.67M -1.50M -0.93M -0.06M
Selling general administrative 0.73M 0.99M 0.94M 0.67M 0.09M
Gross profit -0.02M -0.03M -0.06M -0.16M -
Reconciled depreciation 0.11M 0.11M 0.11M 0.02M -
Ebit - - - -0.75M -0.06M
Ebitda - - - -0.91M -0.06M
Operating income -1.21M -1.79M -1.57M -0.93M -0.06M
Other operating expenses - - - - -0.05M
Interest expense 0.00M 0.01M 0.01M 0.00M -
Tax provision -0.10M -0.13M -0.08M 0.00M 0.00M
Interest income 0.00M 0.00M 0.00M - -
Net interest income -0.00M -0.01M -0.01M -0.00M -0.00M
Income tax expense - - - 0.00M -
Total revenue 0.05M 0.06M 0.01M 0.00M 0.00M
Total operating expenses 1.27M 1.85M 1.58M 0.93M 0.06M
Cost of revenue 0.07M 0.08M 0.07M 0.16M -
Net income from continuing ops -1.11M -1.67M -1.50M -0.93M -0.06M
Net income applicable to common shares - - - -0.93M -0.06M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 3.01M 3.50M 5.26M 4.03M 0.40M
Total liab 0.29M 0.31M 0.40M 0.45M 0.04M
Total stockholder equity 2.72M 3.19M 4.86M 3.58M 0.36M
Other current liab - - - 0.06M -
Common stock - - - 0.78M 0.20M
Capital stock 1.28M 1.03M 1.03M 0.86M 0.20M
Retained earnings -5.29M -4.17M -2.50M -1.00M -0.25M
Other liab - - - 0.01M -
Good will 2.49M 2.49M 2.49M - -
Cash 0.15M 0.64M 2.32M 1.06M 0.36M
Total current liabilities 0.28M 0.29M 0.30M 0.28M 0.04M
Other stockholder equity - - - 0.09M -
Property plant equipment - - - 0.30M -
Total current assets 0.47M 0.86M 2.52M 1.25M 0.40M
Net tangible assets - - - 1.10M 0.36M
Net receivables 0.03M 0.00M 0.01M 0.15M 0.03M
Inventory 0.09M 0.06M 0.05M 0.02M -
Accounts payable 0.11M 0.06M 0.09M 0.14M 0.01M
Non current assets total 2.54M 2.64M 2.74M 2.78M 0.00M
Capital lease obligations 0.00M 0.08M 0.16M 0.23M -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -0.01M -0.06M 0.00M -
Change to liabilities - - - 0.13M 0.00M
Total cashflows from investing activities - - - 0.00M 0.00M
Net borrowings - - - -0.01M -0.01M
Total cash from financing activities - - - 1.37M 1.37M
Change to operating activities - - - -0.10M -0.10M
Net income -1.11M -1.67M -1.50M -0.93M -0.06M
Change in cash -0.49M -1.68M 1.26M 0.70M -0.09M
Begin period cash flow 0.64M 2.32M 1.06M 0.36M 0.45M
End period cash flow 0.15M 0.64M 2.32M 1.06M 0.36M
Total cash from operating activities -1.01M -1.59M -1.38M -0.67M -0.09M
Issuance of capital stock 0.64M 0.00M 2.95M 1.75M -
Depreciation 0.11M 0.11M 0.11M 0.02M 0.02M
Change to inventory -0.02M -0.02M -0.02M - -
Change to account receivables - - - 0.03M -0.03M
Sale purchase of stock - - - -0.37M -
Other cashflows from financing activities - - - -0.37M -0.37M
Change to netincome - - - 0.18M 0.18M
Capital expenditures 0.01M 0.01M 0.06M 0.01M 0.01M
Change in working capital -0.02M -0.03M -0.03M 0.07M -0.03M
Stock based compensation 0.02M 0.00M 0.00M - -
Other non cash items -0.00M - - 0.18M -
Free cash flow -1.02M -1.60M -1.44M -0.68M -0.09M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
BSFAF
BSF Enterprise Plc
-
-%
0.05 - - 68.67 0.73 52.45
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38

Profile*

BSF Enterprise Plc

BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.

2 Portman Street, London, United Kingdom, W1H 6DU

14

Name Title Year Born
Dr. Che J. Connon CEO, MD & Executive Director 1972
Mr. Geoffrey Robert Baker B.Com., L.L.B., LL.B., M.B.A., MBA Company Secretary & Non-Executive Director 1956
Mr. Graham John William Duncan Chief Financial Officer 1963
Mr. Ricardo Gouveia C.S.O NA
Mr. Marcelo Bravo Chief Business Officer NA
Mr. Geoffrey Robert Baker B.Com., L.L.B., M.B.A. Executive Chairman 1956
Dr. Che John Connon CEO, MD & Executive Director 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…